Caffeine / cycD1/CCND1 Cancer Research Results

Caff, Caffeine: Click to Expand ⟱
Features:
Caffeine is a natural chemical with stimulant effects. It is found in coffee, tea, cola, cocoa, guarana, yerba mate, and over 60 other products.

Caffeine (CAF; 1,3,7-trimethylxanthine) — dietary methylxanthine (natural product / drug) found in coffee/tea/cacao and used in OTC stimulants and some analgesic combinations. Sources: coffee/tea, supplements, OTC meds.

Primary mechanisms (conceptual rank):
1) Adenosine receptor antagonism (A1/A2A) → wakefulness, neuromodulation
2) ↑ Catecholamines / CNS arousal → performance + mood effects
3) PDE inhibition (cAMP/cGMP ↑) (high concentration only)
4) Cell-cycle checkpoint interference (ATM/ATR-related) (high concentration only)

Bioavailability / PK relevance: Rapid oral absorption; widely distributed (including CNS); hepatic metabolism (CYP1A2) with large inter-individual variability; tolerance develops with habitual use.

In-vitro vs oral exposure: Many “anti-cancer” mechanisms rely on supra-physiologic concentrations (PDE inhibition, checkpoint override) vs typical dietary plasma levels; clinically relevant mechanism is adenosine antagonism. This is a major translation constraint. Physiologic human exposures after ordinary intake are in the low micromolar range relevant to adenosine receptor occupancy, whereas many anticancer in-vitro effects commonly attributed to caffeine, especially PDE inhibition, Ca²⁺ release, and checkpoint override, usually require far higher concentrations, often approaching high-micromolar to millimolar ranges.

Clinical evidence status: Extensive human data for alertness/performance; oncology evidence is mainly epidemiologic + preclinical (no anticancer indication).

Natural stimulant

-Caffeine appears to interact with several pathways relevant to cancer biology—including adenosine receptor signaling, DNA damage response, cell cycle regulation, apoptosis, PI3K/Akt/mTOR, and NF-κB
—Its overall impact likely depends on the cancer type, stage, microenvironment, and the dosage administered

Caffeine — Cancer vs Normal Cell Pathway Map

RankPathway / AxisCancer CellsNormal CellsTSFPrimary EffectNotes / Interpretation
1Adenosine signaling (A1/A2A antagonism) ↓ adenosine-mediated suppression (context-dependent)↑ arousal/neuromodulationP/R Immune + signaling tone shift A2A antagonism can be immunostimulatory in tumor-microenvironment contexts; not a tumor-directed cytotoxin and highly context-dependent.
2cAMP signaling / catecholamine tone ↔ (context-dependent)↑ (acute stimulation)P/R Systemic stimulation Stress-hormone effects can be bidirectional for cancer biology depending on context; not a central anticancer mechanism.
3DNA damage response checkpoints (ATM/ATR) ↓ checkpoints (high concentration only)↓ checkpoints (high concentration only)P/R S/G2 checkpoint override Classic in vitro effect used to radiosensitize/chemosensitize; translation limited by concentration requirements.
4Cell cycle / proliferation ↓ or ↔ (model-dependent; high concentration only)↔R/G Cytostatic effects (experimental) Observed in vitro; not consistent at dietary exposures.
5Apoptosis ↑ (high concentration only)↔R/G Experimental cytotoxicity Typically downstream of checkpoint disruption/ROS stress in vitro.
6PDE inhibition ↑ cAMP/cGMP (high concentration only)↑ cAMP/cGMP (high concentration only)P/R Second-messenger amplification PDE inhibition is not dominant at typical intake; becomes relevant only at higher exposures.
7ROS ↔ / ↑ (high concentration only)↔P/R Not a primary redox drug Some models show oxidative stress at high dose; not canonical at physiologic exposure.
8NRF2 ↔↔R/G No primary modulation Not a canonical caffeine-first axis.
9HIF-1α ↔ (limited; model-dependent)↔G Not primary Any hypoxia-pathway effects are indirect and not robustly classed as core.
10Ferroptosis ↔ (not established)↔R/G Not canonical No consistent ferroptosis program attributed to caffeine.
11Ca²⁺ signaling ↔↔P/R No primary role Not a dominant mechanistic axis at typical intake.
12Clinical Translation Constraint ↓ (constraint)↓ (constraint)— Exposure + tolerance + sleep effects Most tumor-directed mechanisms require high concentrations; chronic use limited by sleep disruption/anxiety in susceptible individuals and tolerance to stimulant effects.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Caffeine — AD relevance: Strong mechanistic fit via adenosine A2A antagonism (synaptic plasticity + neuroinflammation modulation). Human data support acute attention benefits; dementia/AD risk signals are largely observational (not disease-modifying approval).

Primary mechanisms (conceptual rank):
1) A2A antagonism → ↑ synaptic efficiency / plasticity
2) ↓ Neuroinflammation (microglial tone; cytokine signaling) (context-dependent)
3) ↓ Aβ/tau-associated toxicity pathways (preclinical; model-dependent)
4) Cerebrovascular / glymphatic-sleep tradeoffs (alertness vs sleep architecture effects)

Bioavailability / PK relevance: Rapid CNS penetration; effects are acute (minutes–hours) but chronic patterns depend on tolerance and sleep timing.

Clinical evidence status: Supportive (symptom/attention); AD disease-modifying efficacy not established.

Caffeine — AD / Neurodegeneration Pathway Map

RankPathway / AxisCellsTSFPrimary EffectNotes / Interpretation
1Adenosine A2A antagonism (synaptic plasticity) ↑P/R Improved signaling efficiency Core neuro mechanism; overlaps with the rationale for A2A antagonists in neurodegeneration frameworks.
2Neuroinflammation (microglial activation; cytokines) ↓ (context-dependent)R/G Lower inflammatory stress Often attributed to adenosine-pathway modulation; magnitude is model- and state-dependent.
3ROS / mitochondrial stress ↔ / ↓ (supportive)P/R Resilience support (secondary) Not a primary antioxidant; changes are typically indirect via signaling state and inflammation.
4Aβ / tau-associated pathology ↔ / ↓ (preclinical; model-dependent)G Reduced proteotoxic stress (hypothesis) Evidence is stronger in models than in biomarker-confirmed human AD studies.
5Ca²⁺ excitotoxicity interplay ↔ (indirect)P/R Not primary Could be secondary to synaptic modulation; treat as secondary unless explicit Ca²⁺ endpoints exist.
6Sleep architecture / glymphatic coupling ↑ alertness; ↓ sleep (timing-dependent)R/G Tradeoff axis Potential benefit via daytime function but potential harm if it chronically degrades sleep quality (sleep is relevant to amyloid clearance hypotheses).
7Clinical Translation Constraint ↓ (constraint)— Timing + tolerance + heterogeneity Benefits depend strongly on dosing/timing and individual sensitivity; not disease-modifying therapy.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
1230- CA,  Caff,    Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - Human, NA, NA
TumVol↓, TumCG↓, ER(estro)↓, cycD1/CCND1↓, IGF-1R↓, p‑Akt↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

p‑Akt↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1R↓, 1,   TumCG↓, 1,  

Hormonal & Nuclear Receptors ⓘ

ER(estro)↓, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:52  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page